Portfolio news Archives - Page 5 of 5

Human immune cells can eliminate cancer cells. Anaveon has developed a special antibody to boost the body’s own defense mechanism. The picture shows an electron-microscopic view of one of the immune system’s CD8 killer cells. (Image: NIAID/flickr)

BaseLaunch backed Anaveon received funding

Onur Boyman, an immunologist working at the University Hospital Zurich and UZH, has joined forces with Andreas Katopodis to establish Anaveon, a BaseLaunch participant. Aiming to translate…

Jérémie Meyer20.06.2018

Portfolio news

BaseLaunch accelerated Polyneuron raises new financing

Polyneuron Pharmaceuticals, a BaseLaunch participant, has successfully raised over 3 million Swiss francs in a financing round. The Basel-based pharmaceutical company is developing an active…

Jérémie Meyer14.05.2018

Portfolio news

Biotech VCs are backing more rounds and making bigger bets

Biotech is a lot like venture capital. Vast amounts of research, testing and marketing go into a wide range of therapies. But in the end,…

Jérémie Meyer10.03.2018

Portfolio news

BaseLaunch backed Anaveon received funding

BaseLaunch accelerated Polyneuron raises new financing

Biotech VCs are backing more rounds and making bigger bets

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us